LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alpha-1-Antitrypsin Gene Replacement Therapy Cures Emphysema in Mouse Model

By LabMedica International staff writers
Posted on 19 Jul 2016
Image: A crystal structure model of the surface of the AAV-2 serotype of adeno-associated virus (Photo courtesy of Wikimedia Commons).
Image: A crystal structure model of the surface of the AAV-2 serotype of adeno-associated virus (Photo courtesy of Wikimedia Commons).
A virus-like vector loaded with the gene for production of the enzyme alpha-1-antitrypsin (AAT) successfully established production of the protein in the lungs of mice serving as a model for human emphysema.

Alpha-1-antitrypsin protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. In its absence (such as in alpha 1-antitrypsin deficiency or AATD), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs, resulting in respiratory complications such as emphysema, or COPD (chronic obstructive pulmonary disease) in adults and cirrhosis in adults or children.

Gene therapy to reinstate AAT production in emphysema patients has been considered as an attractive alternative to the current therapy regime of weekly intravenous infusion of the normal AAT protein.

In one approach to developing gene therapy for treatment of emphysema, investigators at Boston Medical College (MA, USA) used a lung-targeted adeno-associated virus (AAV) vector to transport the AAT gene (SERPINA1) to the lungs of mice serving as a model for the human disease.

The investigators reported in the June 29, 2016, online edition of the journal Molecular Therapy - Methods & Clinical Development that the genes delivered in a single injection of lung-directed AAV2/8 were able to achieve therapeutic AAT protein levels within the lung epithelial lining fluid, and that gene expression persisted for at least 52 weeks. Enzyme levels reached after AAT gene delivery were sufficient to relieve the severity of experimental emphysema in the mice. They also found that the same injection of AAV2/8 efficiently transduced liver cells, a finding that may have significance for AAV-based human gene therapy studies.

"These results support direct transgene delivery to the lung as a potential alternative approach to achieve the goal of developing a gene therapy for AATD," said senior author Dr. Andrew Wilson, assistant professor of medicine at Boston Medical College.

Related Links:
Boston Medical College


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more